QQQ   348.68 (+1.19%)
AAPL   162.75 (+1.92%)
MSFT   305.50 (+2.96%)
FB   301.00 (+2.16%)
GOOGL   2,638.76 (+2.09%)
AMZN   2,862.72 (+3.07%)
TSLA   874.70 (-6.69%)
NVDA   224.10 (-1.59%)
BABA   113.56 (+0.17%)
NIO   21.82 (-3.71%)
AMD   105.60 (-4.62%)
CGC   7.02 (-2.90%)
MU   81.17 (-0.98%)
GE   90.46 (+1.28%)
T   24.39 (+0.58%)
F   19.94 (+0.15%)
DIS   137.54 (+2.95%)
AMC   15.07 (-5.46%)
PFE   54.43 (+2.68%)
ACB   3.91 (-3.69%)
BA   194.18 (-0.05%)
QQQ   348.68 (+1.19%)
AAPL   162.75 (+1.92%)
MSFT   305.50 (+2.96%)
FB   301.00 (+2.16%)
GOOGL   2,638.76 (+2.09%)
AMZN   2,862.72 (+3.07%)
TSLA   874.70 (-6.69%)
NVDA   224.10 (-1.59%)
BABA   113.56 (+0.17%)
NIO   21.82 (-3.71%)
AMD   105.60 (-4.62%)
CGC   7.02 (-2.90%)
MU   81.17 (-0.98%)
GE   90.46 (+1.28%)
T   24.39 (+0.58%)
F   19.94 (+0.15%)
DIS   137.54 (+2.95%)
AMC   15.07 (-5.46%)
PFE   54.43 (+2.68%)
ACB   3.91 (-3.69%)
BA   194.18 (-0.05%)
QQQ   348.68 (+1.19%)
AAPL   162.75 (+1.92%)
MSFT   305.50 (+2.96%)
FB   301.00 (+2.16%)
GOOGL   2,638.76 (+2.09%)
AMZN   2,862.72 (+3.07%)
TSLA   874.70 (-6.69%)
NVDA   224.10 (-1.59%)
BABA   113.56 (+0.17%)
NIO   21.82 (-3.71%)
AMD   105.60 (-4.62%)
CGC   7.02 (-2.90%)
MU   81.17 (-0.98%)
GE   90.46 (+1.28%)
T   24.39 (+0.58%)
F   19.94 (+0.15%)
DIS   137.54 (+2.95%)
AMC   15.07 (-5.46%)
PFE   54.43 (+2.68%)
ACB   3.91 (-3.69%)
BA   194.18 (-0.05%)
QQQ   348.68 (+1.19%)
AAPL   162.75 (+1.92%)
MSFT   305.50 (+2.96%)
FB   301.00 (+2.16%)
GOOGL   2,638.76 (+2.09%)
AMZN   2,862.72 (+3.07%)
TSLA   874.70 (-6.69%)
NVDA   224.10 (-1.59%)
BABA   113.56 (+0.17%)
NIO   21.82 (-3.71%)
AMD   105.60 (-4.62%)
CGC   7.02 (-2.90%)
MU   81.17 (-0.98%)
GE   90.46 (+1.28%)
T   24.39 (+0.58%)
F   19.94 (+0.15%)
DIS   137.54 (+2.95%)
AMC   15.07 (-5.46%)
PFE   54.43 (+2.68%)
ACB   3.91 (-3.69%)
BA   194.18 (-0.05%)
NASDAQ:AADI

Aadi Bioscience Stock Competitors

$18.70
-0.16 (-0.85%)
(As of 01/27/2022 11:56 AM ET)
Add
Compare
Today's Range
$18.57
$19.10
50-Day Range
$18.47
$25.85
52-Week Range
$14.31
$49.80
Volume
424 shs
Average Volume
159,173 shs
Market Capitalization
$390.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.51

Aadi Bioscience (NASDAQ:AADI) Vs. TVTX, SUPN, PRTA, ISEE, DVAX, MORF, ZGNX, BCYC, TGTX, and ERAS

Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Prothena (PRTA), IVERIC bio (ISEE), Dynavax Technologies (DVAX), Morphic (MORF), Zogenix (ZGNX), Bicycle Therapeutics (BCYC), TG Therapeutics (TGTX), and Erasca (ERAS). These companies are all part of the "pharmaceutical preparations" industry.

Aadi Bioscience vs.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, community ranking, media sentiment and profitability.

Supernus Pharmaceuticals currently has a consensus target price of $39.50, indicating a potential upside of 34.86%. Aadi Bioscience has a consensus target price of $47.50, indicating a potential upside of 154.01%. Given Aadi Bioscience's higher probable upside, analysts plainly believe Aadi Bioscience is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 1 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 0.00 beat Supernus Pharmaceuticals' score of -0.38 indicating that Aadi Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aadi Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Supernus Pharmaceuticals has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$520.40 million2.98$126.95 million$1.5119.42
Aadi Bioscience$15 million26.05-$4.32 million-$13.37-1.40

Supernus Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.

Supernus Pharmaceuticals has a net margin of 14.49% compared to Aadi Bioscience's net margin of 0.00%. Supernus Pharmaceuticals' return on equity of 10.56% beat Aadi Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals 14.49% 10.56% 5.33%
Aadi Bioscience N/A -37.67% -34.57%

99.6% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.5% of Aadi Bioscience shares are owned by institutional investors. 8.0% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Supernus Pharmaceuticals received 442 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 74.58% of users gave Supernus Pharmaceuticals an outperform vote while only 53.85% of users gave Aadi Bioscience an outperform vote.

CompanyUnderperformOutperform
Supernus PharmaceuticalsOutperform Votes
449
74.58%
Underperform Votes
153
25.42%
Aadi BioscienceOutperform Votes
7
53.85%
Underperform Votes
6
46.15%

Summary

Supernus Pharmaceuticals beats Aadi Bioscience on 12 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Aadi Bioscience (NASDAQ:AADI) vs. Its Competitors

TypeAadi BiosciencePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$390.72M$5.69B$4.56B$6.83B
Dividend YieldN/A2.56%2.08%2.81%
P/E Ratio-1.4013.5016.3818.15
Price / Sales26.05467.855,596.65220.81
Price / CashN/A163.8260.8368.55
Price / Book1.368.187.278.57
Net Income-$4.32M$99.84M$99.04M$156.53M
7 Day Performance-5.08%-5.75%-5.47%-3.95%
1 Month Performance-23.95%-19.27%-15.94%-12.44%
1 Year Performance106.06%-33.29%-21.95%-7.77%

Aadi Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVTX
Travere Therapeutics
1.5798 of 5 stars
$25.41
-4.5%
$32.40
-27.5%
+0.8%$1.56B$198.32M-5.57262Insider Selling
Analyst Revision
News Coverage
Gap Up
SUPN
Supernus Pharmaceuticals
2.3948 of 5 stars
$29.33
-0.1%
$39.50
-34.7%
-5.9%$1.55B$520.40M19.42563Analyst Revision
News Coverage
PRTA
Prothena
2.6498 of 5 stars
$33.01
-2.2%
$67.50
-104.5%
+154.4%$1.54B$850K32.0566
ISEE
IVERIC bio
2.3181 of 5 stars
$12.90
-0.9%
$22.00
-70.5%
+136.5%$1.48BN/A-11.6257
DVAX
Dynavax Technologies
2.5881 of 5 stars
$12.27
-0.7%
$23.50
-91.5%
+100.2%$1.47B$46.55M-35.06245
MORF
Morphic
2.3598 of 5 stars
$39.37
-4.8%
$77.67
-97.3%
+27.4%$1.46B$44.94M-14.8089
ZGNX
Zogenix
1.8581 of 5 stars
$25.94
-0.0%
$32.10
-23.7%
+29.0%$1.45B$13.64M-5.96218
BCYC
Bicycle Therapeutics
2.2314 of 5 stars
$47.57
-0.5%
$72.88
-53.2%
+78.2%$1.40B$10.39M-16.462,020
TGTX
TG Therapeutics
2.4417 of 5 stars
$9.78
-42.1%
$53.50
-447.0%
-72.2%$1.38B$150K-3.70272Analyst Report
Gap Up
Trading Halted
ERAS
Erasca
1.2132 of 5 stars
$11.41
-1.1%
$25.25
-121.3%
N/A$1.38BN/A0.002,021
BBIO
BridgeBio Pharma
2.5798 of 5 stars
$9.28
-5.0%
$55.29
-495.8%
-84.4%$1.37B$8.25M-2.37391Analyst Revision
VERV
Verve Therapeutics
2.0464 of 5 stars
$28.33
-4.7%
$71.20
-151.3%
N/A$1.36BN/A0.0063Gap Up
FGEN
FibroGen
1.8131 of 5 stars
$14.70
-1.4%
$29.50
-100.7%
-70.4%$1.36B$176.32M-6.31599
AMRN
Amarin
2.1083 of 5 stars
$3.41
-0.6%
$9.25
-171.3%
-54.1%$1.35B$614.06M84.002,020Analyst Revision
Gap Up
AMRX
Amneal Pharmaceuticals
2.5681 of 5 stars
$4.38
-1.1%
$7.88
-79.8%
-12.5%$1.32B$1.99B48.676,000Analyst Upgrade
Analyst Revision
XENE
Xenon Pharmaceuticals
2.2998 of 5 stars
$25.58
-3.5%
$44.00
-72.0%
+75.0%$1.32B$32.17M-15.69129Options Volume
Analyst Revision
PTGX
Protagonist Therapeutics
2.0265 of 5 stars
$27.60
-3.0%
$59.71
-116.4%
+23.1%$1.32B$28.63M-11.4579Gap Up
RXDX
Prometheus Biosciences
2.3448 of 5 stars
$33.30
-2.6%
$42.86
-28.7%
+26.8%$1.30B$1.23M0.0026
NUVB
Nuvation Bio
2.3667 of 5 stars
$5.84
-2.2%
$17.40
-197.9%
N/A$1.27BN/A0.0036
LYEL
Lyell Immunopharma
1.7848 of 5 stars
$5.28
-3.0%
$24.25
-359.3%
N/A$1.26BN/A0.00189Gap Up
MYOV
Myovant Sciences
1.8114 of 5 stars
$13.00
-0.4%
$23.75
-82.7%
-42.4%$1.21B$59.32M-4.98407Earnings Report
News Coverage
Gap Up
AMPH
Amphastar Pharmaceuticals
2.2148 of 5 stars
$25.10
-1.9%
$23.67
-5.7%
+28.8%$1.20B$349.85M34.861,980
NGM
NGM Biopharmaceuticals
2.3792 of 5 stars
$15.29
-5.2%
$35.00
-128.9%
-45.3%$1.18B$87.37M-9.50210Gap Up
ENTA
Enanta Pharmaceuticals
2.4681 of 5 stars
$56.63
-1.2%
$90.25
-59.4%
+17.1%$1.15B$97.07M-14.48141
INVA
Innoviva
1.7165 of 5 stars
$15.91
-2.1%
N/A+24.5%$1.11B$336.79M5.105Upcoming Earnings
ADCT
ADC Therapeutics
1.9514 of 5 stars
$15.42
-2.1%
$45.20
-193.1%
-53.5%$1.06B$2.34M-4.70208
CDMO
Avid Bioservices
2.4814 of 5 stars
$17.19
-1.4%
$31.67
-84.2%
+23.7%$1.06B$95.87M132.24255Gap Up
IMGN
ImmunoGen
1.8931 of 5 stars
$5.19
-2.3%
$9.50
-83.0%
-30.6%$1.05B$132.30M-15.2679
PROC
Procaps Group S.A
2.2417 of 5 stars
$9.31
-1.0%
$13.00
-39.6%
N/A$1.05B$106.83M0.00N/ANews Coverage
KROS
Keros Therapeutics
2.1665 of 5 stars
$44.45
-4.3%
$86.67
-95.0%
-30.3%$1.04B$10M-16.4035
PRTC
PureTech Health
1.3665 of 5 stars
$36.00
-1.5%
$71.00
-97.2%
-36.3%$1.04B$11.77M0.0066
RCKT
Rocket Pharmaceuticals
2.3531 of 5 stars
$15.63
-2.0%
$65.25
-317.5%
-70.3%$1.01BN/A-5.09101
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$58.65
-5.0%
$177.57
-202.8%
-48.7%$1.00BN/A-4.0042Gap Up
MOR
MorphoSys
1.2032 of 5 stars
$7.28
-0.8%
$27.08
-272.0%
-76.3%$996.84M$374.30M-5.52615Gap Up
MRUS
Merus
1.7298 of 5 stars
$25.42
-1.7%
$40.20
-58.1%
-14.2%$986.60M$29.94M-10.96117
AXSM
Axsome Therapeutics
2.482 of 5 stars
$24.96
-3.0%
$89.22
-257.5%
-64.8%$940.79MN/A-7.4560Analyst Revision
News Coverage
Gap Up
RANI
Rani Therapeutics
1.5798 of 5 stars
$19.00
-21.8%
$23.50
-23.7%
N/A$931.04MN/A0.002,021Lockup Expiration
Gap Down
ORGO
Organogenesis
2.7998 of 5 stars
$7.18
-1.9%
$23.00
-220.3%
-31.4%$923.66M$338.30M15.61910
RETA
Reata Pharmaceuticals
2.4498 of 5 stars
$24.81
-6.5%
$85.00
-242.6%
-77.4%$902.89M$9.02M-3.21267Gap Up
KURA
Kura Oncology
1.6331 of 5 stars
$13.45
-5.2%
$40.00
-197.4%
-56.9%$895.18MN/A-7.0189
MNKD
MannKind
1.6498 of 5 stars
$3.56
-2.2%
$6.30
-77.0%
-0.8%$894.47M$65.14M-11.13241
RVNC
Revance Therapeutics
2.3781 of 5 stars
$12.45
-2.2%
$23.60
-89.6%
-54.2%$893.85M$15.32M-2.77470Gap Up
CRNX
Crinetics Pharmaceuticals
2.1781 of 5 stars
$18.41
-2.9%
$36.80
-99.9%
+25.8%$874.48M$70K-6.6293
HRTX
Heron Therapeutics
1.9248 of 5 stars
$8.51
-2.2%
$26.00
-205.5%
-50.5%$867.47M$88.64M-3.56223
GHRS
GH Research
1.7464 of 5 stars
$17.16
-4.1%
$26.42
-53.9%
N/A$866.94MN/A0.008Gap Up
ANAB
AnaptysBio
1.8531 of 5 stars
$30.80
-2.0%
$35.80
-16.2%
+28.6%$851.47M$75M110.0094Analyst Downgrade
Gap Up
DAWN
Day One Biopharmaceuticals
2.0265 of 5 stars
$13.63
-1.6%
$37.33
-173.9%
N/A$844.09MN/A0.0020Positive News
VNDA
Vanda Pharmaceuticals
2.4814 of 5 stars
$14.82
-0.5%
$20.00
-35.0%
+1.8%$825.65M$248.17M24.30292Analyst Upgrade
News Coverage
CNTA
Centessa Pharmaceuticals
2.1398 of 5 stars
$9.17
-2.1%
$38.00
-314.4%
N/A$824.39MN/A0.002,021
ZEAL
Zealand Pharma A/S
0.8798 of 5 stars
$18.71
-0.2%
N/A-49.1%$816.39M$54.13M-4.31329
This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.